Patient . | Age (years) . | Pre-procedural left ventricular (LV) ejection fraction (%) . | Comorbidities . | Body mass index (BMI) . | Medications . | Known allergies . | Anaesthesia . | Biochemistry results . | Total heparin (IU) administered . | Time interval from last heparin dose to protamine (min) . | Time interval post-protamine infusion to onset of cardiac arrest (min) . | Other pharmacological agents given peri-procedure (apart from GA) . |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 72 | >55% | Ischaemic heart disease (IHD), permanent pacemaker (PPM) for symptomatic bradycardia | 28.8 |
| None | General anaesthetic (GA):
|
| 19 000 | 90 | 10 | Intravenous ondansetron 4 mg, paracetamol 1 g, metaraminol 0.5 mg slow bolus |
2 | 60 | 30% | Dilated cardiomyopathy (DCM), cardiac resynchronization therapy-defibrillator (CRT-D) in situ | 38.5 |
| None | Conscious sedation
|
| 17 000 | 60 | 3 | Intravenous morphine (5 mg) |
3 | 67 | 55% | Chronic kidney disease (CKD) 3 | 28.4 |
| None | GA:
|
| 15 000 | 60 | 10 | Nil |
Patient . | Age (years) . | Pre-procedural left ventricular (LV) ejection fraction (%) . | Comorbidities . | Body mass index (BMI) . | Medications . | Known allergies . | Anaesthesia . | Biochemistry results . | Total heparin (IU) administered . | Time interval from last heparin dose to protamine (min) . | Time interval post-protamine infusion to onset of cardiac arrest (min) . | Other pharmacological agents given peri-procedure (apart from GA) . |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 72 | >55% | Ischaemic heart disease (IHD), permanent pacemaker (PPM) for symptomatic bradycardia | 28.8 |
| None | General anaesthetic (GA):
|
| 19 000 | 90 | 10 | Intravenous ondansetron 4 mg, paracetamol 1 g, metaraminol 0.5 mg slow bolus |
2 | 60 | 30% | Dilated cardiomyopathy (DCM), cardiac resynchronization therapy-defibrillator (CRT-D) in situ | 38.5 |
| None | Conscious sedation
|
| 17 000 | 60 | 3 | Intravenous morphine (5 mg) |
3 | 67 | 55% | Chronic kidney disease (CKD) 3 | 28.4 |
| None | GA:
|
| 15 000 | 60 | 10 | Nil |
Patient . | Age (years) . | Pre-procedural left ventricular (LV) ejection fraction (%) . | Comorbidities . | Body mass index (BMI) . | Medications . | Known allergies . | Anaesthesia . | Biochemistry results . | Total heparin (IU) administered . | Time interval from last heparin dose to protamine (min) . | Time interval post-protamine infusion to onset of cardiac arrest (min) . | Other pharmacological agents given peri-procedure (apart from GA) . |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 72 | >55% | Ischaemic heart disease (IHD), permanent pacemaker (PPM) for symptomatic bradycardia | 28.8 |
| None | General anaesthetic (GA):
|
| 19 000 | 90 | 10 | Intravenous ondansetron 4 mg, paracetamol 1 g, metaraminol 0.5 mg slow bolus |
2 | 60 | 30% | Dilated cardiomyopathy (DCM), cardiac resynchronization therapy-defibrillator (CRT-D) in situ | 38.5 |
| None | Conscious sedation
|
| 17 000 | 60 | 3 | Intravenous morphine (5 mg) |
3 | 67 | 55% | Chronic kidney disease (CKD) 3 | 28.4 |
| None | GA:
|
| 15 000 | 60 | 10 | Nil |
Patient . | Age (years) . | Pre-procedural left ventricular (LV) ejection fraction (%) . | Comorbidities . | Body mass index (BMI) . | Medications . | Known allergies . | Anaesthesia . | Biochemistry results . | Total heparin (IU) administered . | Time interval from last heparin dose to protamine (min) . | Time interval post-protamine infusion to onset of cardiac arrest (min) . | Other pharmacological agents given peri-procedure (apart from GA) . |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 72 | >55% | Ischaemic heart disease (IHD), permanent pacemaker (PPM) for symptomatic bradycardia | 28.8 |
| None | General anaesthetic (GA):
|
| 19 000 | 90 | 10 | Intravenous ondansetron 4 mg, paracetamol 1 g, metaraminol 0.5 mg slow bolus |
2 | 60 | 30% | Dilated cardiomyopathy (DCM), cardiac resynchronization therapy-defibrillator (CRT-D) in situ | 38.5 |
| None | Conscious sedation
|
| 17 000 | 60 | 3 | Intravenous morphine (5 mg) |
3 | 67 | 55% | Chronic kidney disease (CKD) 3 | 28.4 |
| None | GA:
|
| 15 000 | 60 | 10 | Nil |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.